阿托伐他汀
医学
MAPK/ERK通路
药理学
过氧化物酶体增殖物激活受体
缺血
内分泌学
内科学
受体
激酶
生物
生物化学
作者
Zheng Li,Yumin Luo,Jiahui Zhang
出处
期刊:Neuro endocrinology letters
日期:2021-09-10
卷期号:42 (5): 331-338
摘要
Objective The purpose of this study was to investigated whether pretreated with Atorvastatin be helpful in diabetic or wild-type mice, and clarify the possible mechanisms. Methods C57/B6 and ob/ob mice treated with atorvastatin or not were subjected to middle cerebral artery occlusion (MCAO), which were killed after 2h of occlusion following by 22h of reperfusion. We used Neurological Severity Scores (NSS) to assess the severity of brain injury, and TTC staining was used to measure the infraction volume. Protein levels of PGC-1α, vascular endothelial growth factor (VEGF), angiopoietin-1 (Ang-1), Bcl2, Bax and signaling pathway protein of mitogen-activated protein kinase (MAPK) were estimated by western blot. Results Atorvastatin could slake the cerebral ischemic/ reperfusion injury in ob/ob diabetic mice, but do nothing on wild-type mice. The expression of PGC-1α and related angiogenic factors such as VEGF and Ang-1 were lower in the diabetic mice after MCAO than wild-type, which could be effective reversed by atorvastatin pretreatment before MCAO. This may be one of the possible mechanisms for atorvastatin to alleviate ischemic injury. MAPK pathway and apoptosis-related proteins were also involved in this course. Conclusion Impaired angiogenesis mediated by PGC-1α plays an important role in exacerbating ischemic cerebral insults in diabetic mice, and pretreatment with atorvastatin before MCAO has a protective effect through the regulation of PGC-1α and angiogenic factors.
科研通智能强力驱动
Strongly Powered by AbleSci AI